Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.

The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone. Subjects were randomly assigned to single-blind therapy with olanzapine (10 mg/d), risperidone (4 mg/d), or placebo for approximately 3 wk. Insulin sensitivity was assessed pre- and posttreatment using a 2-step, hyperinsulinemic, euglycemic clamp. Glucose and insulin responses were also assessed by a mixed meal tolerance test. Of the 64 subjects randomized, 22, 14, and 19 in the olanzapine, risperidone, and placebo groups, respectively, completed the study procedures. There were no significant within-group changes in the glucose disposal rate or the insulin sensitivity index for the active therapy groups. Further, the results of the mixed meal tolerance test did not demonstrate clinically significant changes in integrated glucose metabolism during treatment with these medications. In summary, this study did not demonstrate significant changes in insulin sensitivity in healthy subjects after 3 wk of treatment with olanzapine or risperidone.

[1]  J. Connell,et al.  THE EUGLYCAEMIC HYPERINSULINAEMIC CLAMP: AN EVALUATION OF CURRENT METHODOLOGY , 1997, Clinical and experimental pharmacology & physiology.

[2]  E. Rinderknecht,et al.  Nonsuppressible insulin-like activity (NSILA) from human serum: recent accomplishments and their physiologic implications. , 1978, Metabolism: clinical and experimental.

[3]  I. Heuser,et al.  Major depression and impaired glucose tolerance , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[4]  L. Byberg,et al.  Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril , 2000, Journal of Human Hypertension.

[5]  J. Amsterdam,et al.  Insulin resistance after oral glucose tolerance testing in patients with major depression. , 1988, The American journal of psychiatry.

[6]  D. Taylor,et al.  Atypical antipsychotics and hyperglycaemia , 2001, International clinical psychopharmacology.

[7]  M. Schambelan,et al.  Metabolic effects of indinavir in healthy HIV-seronegative men , 2001, AIDS.

[8]  A. Breier,et al.  Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. , 2002, The Journal of clinical endocrinology and metabolism.

[9]  M. Hongo,et al.  Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. , 2000, Metabolism: clinical and experimental.

[10]  M. Schambelan,et al.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study , 2002, AIDS.

[11]  M. Cassader,et al.  An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. , 1983, The Journal of clinical investigation.

[12]  C. Kahn.  Insulin resistance, insulin insensitivity, and insulin unresponsiveness: a necessary distinction. , 1978, Metabolism: clinical and experimental.

[13]  J. Muench,et al.  Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. , 2001, The Journal of the American Board of Family Practice.

[14]  D. Henderson.  Atypical Antipsychotic-Induced Diabetes Mellitus , 2002, CNS drugs.

[15]  C. Berne,et al.  Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. , 1989, BMJ.